Clinical Trial	Number	Phase	Clinical Indication	Drug	Other Names	Antigen Target	Linker	Payload
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (TULIP)	NCT03262935	III	Metastatic Breast Cancer; solid tumors (HER2-expressing breast cancers)	(vic-)trastuzumab duocarmazine	SYD985, Trastuzumab vc-seco-DUBA	ERBB2	Cleavable linker N-[2-(2 maleimidoethoxy)ethoxycarbonyl]-L-valyl-L-citrullinyl-p-aminobenzyl oxycarbonyl-N-[2-(2-hydroxyethoxy)ethyl]- N-[2-(methylamino)ethyl]carbamoyl	Duocarmycin/Seco-DUBA
The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer	NCT04185649	III	HER2-positive locally advanced or metastatic breast cancer with prior trastuzumab treatment	trastuzumab biosimilar	N/A	HER2	Uncleavable Batansine linker	maytansine derivative
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) (ACE-Breast03)	NCT04829604	II	T-DM1-resistant and HER2-low breast cancers	ARX788	ARX788	HER2	Non-cleavable Amberstatin (AS269)	Monomethyl Auristatin F (MMAF)
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)	NCT04504916	II	HER2-negative TNBC	Zilovertamab vedotin	MK-2140, VLS-101	Receptor tyrosine kinase-like orphan receptor 1 (ROR1)	Cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate	Monomethyl auristatin E (MMAE)
RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer	NCT05134519	II	HER2-Positive Breast Cancer	Disitamab vedotin	N/A	HER2	Cleavable protease linker	Monomethyl auristatin E (MMAE)
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene	NCT03602079	I	Amplified HER2 Gene Locally Advanced or Metastatic Breast Cancer	A166	N/A	HER2	Cleavable valine citrulline (Val-Cit) linker	Duostatin-5 (an MMAF derivative)
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2	NCT02952729	I	HER2 Positive Advanced Breast Cancer	XMT-1522	TAK-522	HER2	drug polymer cleavable linker	Auristatin F-hydroxypropylamide (AF-HPA)
Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer	NCT03451162	I	HER2-Positive Breast Cancer	DHES0815A	RG6148	HER2	Disulfide linker	DNA minor groove crosslinking agent pyrrolo[2,1- c][1,4]benzodiazepine monoamide (PBD-MA)
Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients	NCT03281824	I	HER2-Positive Breast Cancer	ALT-P7	N/A	HER2	Cleavable valine citrulline (Val-Cit) linker	Monomethyl auristatin E (MMAE)
B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer (B003-101)	NCT03953833	I	HER2-Positive Recurrent or Metastatic Breast Cancer	B003	N/A	ErbB2	Thioether linker	N/A
N/A	N/A	I	Breast Cancer	LCB14-0110	Trastuzumab-LC-LBG-MMAF, Herceptin-LC-LBG-MMAF	HER2	Proprietary beta-glucuronide linker	MMAF
N/A	N/A	I	HER2-Positive Recurrent or Advanced/Metastatic Breast Cancer	SHR-A1201	N/A	HER2	N/A	N/A
Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors	NCT04146610	I	HER2-Positive Breast Cancer	DP303c	N/A	HER2	N/A	N/A